Predictors of recurrence after conversion therapy in unresectable hepatocellular carcinoma treated with HAIC, bevacizumab, and sintilimab

Predictors of recurrence after conversion therapy in unresectable hepatocellular carcinoma treated with HAIC, bevacizumab, and sintilimab

BackgroundConversion therapy with hepatic arterial infusion chemotherapy (HAIC) combined with bevacizumab and sintilimab has shown promise for unresectable hepatocellular carcinoma (uHCC). However, predictors of postoperative recurrence remain unclear.MethodsWe retrospectively analyzed 112 HCC patie...

Full description

Saved in:
Bibliographic Details
Main Authors: Chang-Fu Liu, Xiao-Hui Zhao, Shi-Bo Zhu, Hai-Peng Yu, Wen-Ge Xing, Hui-Kai Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Immunology
Subjects:
hepatocellular carcinoma
conversion therapy
hepatic arterial infusion chemotherapy
bevacizumab
sintilimab
recurrence
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1644570/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items